NuPathe Inc (PATH) in Focus: Stock Zooms 47.4 Percent

NuPathe Inc (PATH) in Focus: Stock Zooms 47.4 Percent

NuPathe, Inc. (PATH) was a big mover last session, as its shares surged over 47% on the day. The surge came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend for the healthcare stock, as it is now up nearly 94% in the past one-month time frame.

In the last 30 days, the company has seen one negative estimate revision and its Zacks Consensus Estimate also moved lower, suggesting there may be trouble down the road. So make sure to keep an eye on this stock going forward to see if yesterday’s move higher lasts.

NuPathe currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.

DG Value Adds 36.4% YTD As Distressed Stocks Surge

Dov Gertzulin's DG Capital is having a strong year. According to a copy of the hedge fund's letter to investors of its DG Value Partners Class C strategy, the fund is up 36.4% of the year to the end of June, after a performance of 12.8% in the second quarter. The Class C strategy is Read More

Some better-ranked medical stocks include Lannett Company, Inc. (LCI), Jazz Pharmaceuticals plc (JAZZ) and Questcor Pharmaceuticals, Inc. (QCOR). All three companies carry a Zacks Rank #1 (Strong Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>

JAZZ PHARMACEUT (JAZZ): Free Stock Analysis Report

LANNETT INC (LCI): Free Stock Analysis Report

NUPATHE INC (PATH): Free Stock Analysis Report

QUESTCOR PHARMA (QCOR): Free Stock Analysis Report

To read this article on click here.

Zacks Investment Research

No posts to display